Woburn-based ArQule Inc. rallied 12 percent, the most since July 2010. ArQule, a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics, reported that its tivantinib product delayed the progression of cancer in a phase two study of 107 patients. All had liver cancer and had been treated previously. Tivantinib (also known as ARQ 197) is designed to block the activity of a molecule known as c-Met that plays multiple roles in cancer. It is ArQule’s lead product.